DBV Technologies (NASDAQ:DBVT) Trading Down 7.4% - Here's Why

Key Points

• DBV Technologies shares fell 7.4% in midday trading to about $12.01, with trading volume roughly 58% below the average session volume.
• Analyst sentiment remains mixed but leans positive: the consensus rating is “Moderate Buy” with a $48.50 price target, despite recent downgrades from some firms.
• Institutional interest is substantial, with hedge funds including MPM Bioimpact, Adage Capital, and Octagon Capital taking new positions; institutions and hedge funds collectively own 71.74% of the stock.

DBV Technologies S.A. (NASDAQ:DBVT - Get Free Report) shares fell 7.4% during mid-day trading on Friday . The stock traded as low as $12.38 and last traded at $12.01. Approximately 122,596 shares changed hands during mid-day trading, a decline of 58% from the average session volume of 289,946 shares. The stock had previously closed at $12.97.

Analysts Set New Price Targets

Several analysts have commented on the stock. Citizens Jmp increased their price target on shares of DBV Technologies from $47.00 to $55.00 and gave the company a "market outperform" rating in a research report on Tuesday, June 30th. Weiss Ratings downgraded shares of DBV Technologies from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Friday, July 17th. HC Wainwright reiterated a "buy" rating on shares of DBV Technologies in a research note on Tuesday, June 30th. Wall Street Zen cut shares of DBV Technologies from a "hold" rating to a "sell" rating in a research report on Saturday, July 4th. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of DBV Technologies in a research note on Thursday. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $48.50.

DBV Technologies Trading Down 6.6%

The company has a 50-day moving average of $14.37 and a 200-day moving average of $17.62. The company has a market capitalization of $761.35 million, a price-to-earnings ratio of -3.46 and a beta of -0.95.

Hedge Funds Weigh In On DBV Technologies

Several hedge funds have recently modified their holdings of the stock. MPM Bioimpact LLC purchased a new position in shares of DBV Technologies in the 2nd quarter valued at approximately $9,649,000. Adage Capital Partners GP L.L.C. acquired a new position in DBV Technologies during the 2nd quarter valued at approximately $9,659,000. Octagon Capital Advisors LP acquired a new position in DBV Technologies during the 2nd quarter valued at approximately $9,315,000. Two Sigma Investments LP purchased a new position in shares of DBV Technologies in the third quarter worth $167,000. Finally, Citadel Advisors LLC purchased a new position in shares of DBV Technologies in the third quarter worth $220,000. Institutional investors and hedge funds own 71.74% of the company's stock.

DBV Technologies Company Profile

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.